To ask Her Majesty's Government why the use of Ronapreve has been restricted only to people who are currently hospitalised with COVID-19; what assessment they have made of the numbers of patients expected to be treated with Ronapreve in the next 12 months; and what, if any assessment, they have made of the benefits of providing it as prophylaxis for high-risk patients who are not in hospital.
Answered on
19 October 2021
The current supply of Ronapreve is limited globally and the clinical policy prioritises the most vulnerable patients for whom this treatment will have the largest beneficial impact. The use of Ronapreve is being monitored and the interim clinical policy will be updated if supported by the latest evidence.
The number of patients treated by Ronapreve will depend on the infection rate over the next year; the degree of vaccine protection; the availability of Ronapreve and other products; and on National Health Service clinical policy. To date, the evidence has most strongly supported treatment indications, but the evidence on prophylactic use will continue to be actively reviewed.